Trial Profile
Relative Bioavailability and the Effect of Food on the Bioavailability of LY2801653 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2015
Price :
$35
*
At a glance
- Drugs Merestinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 18 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.